FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2964620721> ?p ?o ?g. }

• W2964620721 endingPage "2359" @default.
• W2964620721 startingPage "2349" @default.
• W2964620721 abstract "PURPOSE Tumor-associated antigen cytotoxic T cells (TAA-Ts) represent a new, potentially effective and nontoxic therapeutic approach for patients with relapsed or refractory solid tumors. In this first-in-human trial, we investigated the safety of administering TAA-Ts that target Wilms tumor gene 1, preferentially expressed antigen of melanoma, and survivin to patients with relapsed/refractory solid tumors. MATERIALS AND METHODS TAA-T products were generated from autologous peripheral blood and infused over three dose levels: 1, 2, and 4 × 10 7 cells/m 2 . Patients were eligible for up to eight infusions administered 4 to 7 weeks apart. We assessed dose limiting toxicity during the first 45 days after infusion. Disease response was determined within the context of a phase I trial. RESULTS There were no dose-limiting toxicities. Of 15 evaluable patients, 11 (73%) with stable disease or better at day 45 postinfusion were defined as responders. Six responders remain without progression at a median of 13.9 months (range, 4.1 to 19.9 months) after initial TAA-Ts. Patients who were treated at the highest dose level showed the best clinical outcomes, with a 6-month progression-free survival of 73% after TAA-T infusion compared with a 38% 6-month progression-free survival with prior therapy. Antigen spreading and a reduction in circulating tumor-associated antigens using digital droplet polymerase chain reaction was observed in patients after TAA-T infusion. CONCLUSION TAA-Ts safely induced disease stabilization, prolonged time to progression, and were associated with antigen spreading and a reduction in circulating tumor-associated antigen DNA levels in patients with relapsed/refractory solid tumors without lymphodepleting chemotherapy before infusion. TAA-Ts are a promising new treatment approach for patients with solid tumors." @default.
• W2964620721 created "2019-08-13" @default.
• W2964620721 creator A5007455653 @default.
• W2964620721 creator A5013307500 @default.
• W2964620721 creator A5020298914 @default.
• W2964620721 creator A5033997937 @default.
• W2964620721 creator A5042431577 @default.
• W2964620721 creator A5044759108 @default.
• W2964620721 creator A5051427529 @default.
• W2964620721 creator A5055159427 @default.
• W2964620721 creator A5055376125 @default.
• W2964620721 creator A5057892885 @default.
• W2964620721 creator A5059343454 @default.
• W2964620721 creator A5060160810 @default.
• W2964620721 creator A5064642378 @default.
• W2964620721 creator A5066139971 @default.
• W2964620721 creator A5071593021 @default.
• W2964620721 creator A5072861925 @default.
• W2964620721 creator A5075601460 @default.
• W2964620721 creator A5083853357 @default.
• W2964620721 creator A5084623332 @default.
• W2964620721 creator A5085372074 @default.
• W2964620721 date "2019-09-10" @default.
• W2964620721 modified "2023-10-17" @default.
• W2964620721 title "Immunotherapy of Relapsed and Refractory Solid Tumors With Ex Vivo Expanded Multi-Tumor Associated Antigen Specific Cytotoxic T Lymphocytes: A Phase I Study" @default.
• W2964620721 cites W1903684934 @default.
• W2964620721 cites W1961680179 @default.
• W2964620721 cites W1966837719 @default.
• W2964620721 cites W1974691344 @default.
• W2964620721 cites W1975864832 @default.
• W2964620721 cites W1979718003 @default.
• W2964620721 cites W1980137951 @default.
• W2964620721 cites W1983398046 @default.
• W2964620721 cites W1985328622 @default.
• W2964620721 cites W2002495982 @default.
• W2964620721 cites W2004709238 @default.
• W2964620721 cites W2006436161 @default.
• W2964620721 cites W2006982588 @default.
• W2964620721 cites W2008788809 @default.
• W2964620721 cites W2019607817 @default.
• W2964620721 cites W2024515744 @default.
• W2964620721 cites W2027863358 @default.
• W2964620721 cites W2032458681 @default.
• W2964620721 cites W2038413378 @default.
• W2964620721 cites W2045700626 @default.
• W2964620721 cites W2050645715 @default.
• W2964620721 cites W2051549641 @default.
• W2964620721 cites W2057917996 @default.
• W2964620721 cites W2059311856 @default.
• W2964620721 cites W2064510700 @default.
• W2964620721 cites W2072653755 @default.
• W2964620721 cites W2089041106 @default.
• W2964620721 cites W2091943025 @default.
• W2964620721 cites W2095224412 @default.
• W2964620721 cites W2098357256 @default.
• W2964620721 cites W2110561953 @default.
• W2964620721 cites W2130309988 @default.
• W2964620721 cites W2132923173 @default.
• W2964620721 cites W2134257413 @default.
• W2964620721 cites W2142436421 @default.
• W2964620721 cites W2153712501 @default.
• W2964620721 cites W2157976581 @default.
• W2964620721 cites W2161828728 @default.
• W2964620721 cites W2175268989 @default.
• W2964620721 cites W2185265351 @default.
• W2964620721 cites W2399328737 @default.
• W2964620721 cites W2468472146 @default.
• W2964620721 cites W2564105093 @default.
• W2964620721 cites W2570779139 @default.
• W2964620721 cites W2582851869 @default.
• W2964620721 cites W2783925321 @default.
• W2964620721 cites W2802539836 @default.
• W2964620721 cites W31569885 @default.
• W2964620721 cites W4231483701 @default.
• W2964620721 doi "https://doi.org/10.1200/jco.19.00177" @default.
• W2964620721 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6804838" @default.
• W2964620721 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31356143" @default.
• W2964620721 hasPublicationYear "2019" @default.
• W2964620721 type Work @default.
• W2964620721 sameAs 2964620721 @default.
• W2964620721 citedByCount "46" @default.
• W2964620721 countsByYear W29646207212019 @default.
• W2964620721 countsByYear W29646207212020 @default.
• W2964620721 countsByYear W29646207212021 @default.
• W2964620721 countsByYear W29646207212022 @default.
• W2964620721 countsByYear W29646207212023 @default.
• W2964620721 crossrefType "journal-article" @default.
• W2964620721 hasAuthorship W2964620721A5007455653 @default.
• W2964620721 hasAuthorship W2964620721A5013307500 @default.
• W2964620721 hasAuthorship W2964620721A5020298914 @default.
• W2964620721 hasAuthorship W2964620721A5033997937 @default.
• W2964620721 hasAuthorship W2964620721A5042431577 @default.
• W2964620721 hasAuthorship W2964620721A5044759108 @default.
• W2964620721 hasAuthorship W2964620721A5051427529 @default.
• W2964620721 hasAuthorship W2964620721A5055159427 @default.
• W2964620721 hasAuthorship W2964620721A5055376125 @default.
• W2964620721 hasAuthorship W2964620721A5057892885 @default.
• W2964620721 hasAuthorship W2964620721A5059343454 @default.

• next